Sarepta Therapeutics

Sarepta soars after the FDA asks for quick do-over on Duchenne drug

The FDA updates expanded access drug rules, and Sarepta plunges

UPDATED: The FDA decides that it can’t decide yet on Sarepta’s eteplirsen

What the analysts are saying about Sarepta’s chances at the FDA

In setback, a majority of FDA experts reject Sarepta’s emotional campaign to gain Duchenne drug OK

Patient advocates descend on FDA panel as Sarepta squares off against regulators

FDA bats back Sarepta’s counterattack as a final showdown looms over Duchenne drug